Cheng Xing, Li Ya-Ling, Wang Heng, Zhang Rui-Jing, Fan Ke-Yi, Qi Xiao-Tong, Zheng Guo-Ping, Dong Hong-Lin
Department of Vascular Surgery, The Second Hospital of Shanxi Medical University, Taiyuan 030000, Shanxi Province, China.
Centre for Transplant and Renal Research, Westmead Institute for Medical Research, The University of Sydney, Sydney 2145, New South Wales, Australia.
World J Stem Cells. 2024 Dec 26;16(12):1062-1085. doi: 10.4252/wjsc.v16.i12.1062.
Mesenchymal stem cells (MSCs) are capable of self-renewal and differentiation, and extensive studies have demonstrated their therapeutic potential in atherosclerosis (AS).
To conduct a bibliometric analysis of studies on the use of MSC therapy for AS over the past two decades, assess key trends and provide insights for future research directions.
We systematically searched the Web of Science Core Collection database for articles published between 1999 and 2023, yielding a total of 556 articles. Visual representation and bibliometric analysis of information and trends were facilitated using CiteSpace, the R package 'bibliometrix' and VOSviewer.
The analyzed articles were predominantly from 52 countries/regions, with prominent contributions from China and the United States. A cohort of 3057 authors contributed to these publications, with the works of Libby P distinguished by their influence and citation count. has emerged as the journal with the highest publication volume, prominently disseminating influential papers and identifying citation outbreaks. Furthermore, our analysis identified current research hotspots within the field, focusing on vascular progenitor cells, inflammatory mechanisms, and extracellular vesicles. Emerging research frontiers, such as extracellular vesicles and oxidative stress, have been highlighted as areas of burgeoning interest. Finally, we offer perspectives on the status of research and future directions of MSC therapy in AS.
This comprehensive analysis provides valuable insights for advancing scientific research on MSC therapy for AS. By elucidating pivotal trends and research directions, this study aimed to foster innovation and promote the progress of disciplines in this field, thereby contributing to advancing scientific knowledge and clinical practice.
间充质干细胞（MSCs）具有自我更新和分化能力，大量研究已证明其在动脉粥样硬化（AS）治疗中的潜力。
对过去二十年间使用间充质干细胞治疗动脉粥样硬化的研究进行文献计量分析，评估关键趋势并为未来研究方向提供见解。
我们系统检索了科学网核心合集数据库中1999年至2023年发表的文章，共获得556篇文章。使用CiteSpace、R包“bibliometrix”和VOSviewer对信息和趋势进行可视化呈现和文献计量分析。
分析的文章主要来自52个国家/地区，中国和美国贡献突出。3057名作者参与了这些出版物的撰写，Libby P的作品影响力和被引次数显著。 已成为发表量最高的期刊，突出传播有影响力的论文并识别出引用爆发情况。此外，我们的分析确定了该领域当前的研究热点，重点是血管祖细胞、炎症机制和细胞外囊泡。细胞外囊泡和氧化应激等新兴研究前沿已被突出为新兴关注领域。最后，我们对间充质干细胞治疗动脉粥样硬化的研究现状和未来方向提供了观点。
这一全面分析为推进间充质干细胞治疗动脉粥样硬化的科学研究提供了有价值的见解。通过阐明关键趋势和研究方向，本研究旨在促进该领域的创新和学科发展，从而推动科学知识和临床实践的进步。
